Key Metrics
Factor Lens
Seasonal Performance
Financial Trends
Revenue & Net Income
Earnings Per Share
Margins
Cash Flow
Company Overview
DexCom, Inc. is a medical device company primarily focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for the management of… diabetes and metabolic health by patients, caregivers, and clinicians around the world. The company received FDA approval and commercialized its first product in 2006. Key product offerings include the Dexcom G7 Continuous Glucose Monitoring System (approved December 2022), the Dexcom G7 15 Day system (approved April 2025), the Dexcom G6, Dexcom ONE+ (CE Mark approved November 2023), and Stelo (launched August 2024), an over-the-counter glucose biosensor for adults with prediabetes and Type 2 diabetes who do not use insulin. The company also offers Dexcom Share and Dexcom Follow remote monitoring systems and has entered into multiple collaboration agreements with insulin delivery system providers. The company serves patients with Type 1 and Type 2 diabetes globally, with products cleared for use in the United States, European Union, and other markets. As of December 31, 2025, the company had approximately 3.5 million active customers globally.
- Name
- DexCom, Inc.
- Industry
- Medical Devices
- CEO
- Jacob Leach · President and Chief Executive Officer
- Employees
- —
- IPO Date
- 2018-08-15
- Phone
- (858) 200-0200
- Address
- 6340 Sequence Drive, San Diego, CA 92121
- Website
- www.dexcom.com
Key Executives
| Name | Title | FY Pay |
|---|---|---|
| Kevin Sayer | Executive Chairman of the Board | — |
| Jacob Leach | President and Chief Executive Officer | — |
Latest News
- 2026-04-24
- 2026-04-23
-
2026-04-23
Cwm LLC Sells 91,609 Shares of DexCom, Inc. $DXCM defenseworld.net
-
2026-04-18
Chicago Capital LLC Reduces Position in DexCom, Inc. $DXCM defenseworld.net
-
2026-04-18
Lbp Am Sa Buys 8,296 Shares of DexCom, Inc. $DXCM defenseworld.net
- 2026-04-16
- 2026-04-16
- 2026-04-15